Technology

DongKook Pharmaceutical Co.,Ltd. Reports Cumulative Third-Quarter Sales of 768.6 Billion… Driven by Overseas Beauty Sales

Consolidated Revenue Up 12.4%·Operating Profit Up 6.9% Operating Profit Rises 23.3% on a Standalone Basis

Kim Seung-kwon
2026-11-16 10:24:02
[Edaily Reporter Kim Seung-kwon ] DongKook Pharmaceutical Co.,Ltd.(086450)reported year-over-year increases in both cumulative revenue and operating profit for the first three quarters of this year. Growth was driven by expanded overseas sales in the Health & Beauty business.

DongKook Pharmaceutical Co.,Ltd. announced in a regulatory filing on the 16th that it recorded consolidated cumulative third-quarter revenue of 768.6 billion won and operating profit of 77.2 billion won. These figures represent year-over-year increases of 12.4% and 6.9%, respectively. On a non-consolidated basis, revenue was 658.6 billion won and operating profit was 70.9 billion won, up 17.2% and 23.3%, respectively.



The difference in growth rates between consolidated and standalone results reflects the weak performance of DongKook Life Science Co., Ltd. Sales in the ME business division declined as market conditions for diagnostic equipment deteriorated. Sales and profits also decreased during the process of restructuring the portfolio, including the relocation of a contrast agent production plant for global exports. The company expects profitability to improve once the business restructuring is complete.

Growth in standalone earnings was driven by the Health & Beauty Business Division. In North America, the company expanded its distribution network to include Costco, Ulta Beauty, and Nordstrom. In Japan, the company entered approximately 7,500 local stores, including Don Quijote and Matsumoto Kiyoshi. In the third quarter, it began its expansion into Europe, starting with a launch at the British H&B store Boots. Cumulative sales of its flagship product, “Madeca Cream,” exceeded 100 million units as of last September.

Cumulative sales for the Prescription Drug (ETC) Business Division increased by 8.4% compared to the same period last year. “Uresco,” an improved new drug for benign prostatic hyperplasia approved last December, secured a market share of over 70% in the market for drugs with the same active ingredient within 10 months of its launch. DongKook Pharmaceutical Co.,Ltd. also signed a licensing and supply agreement with Spanish pharmaceutical company FAES FARMA for “Uresco” in Central and South America. Sales in the health functional foods division increased by more than 30% compared to the same period last year.

A DongKook Pharmaceutical Co.,Ltd. official stated, “Our overseas Health & Beauty business is now yielding substantial results, and profitability is improving as we diversify our distribution channels.” The official added, “We plan to sequentially commercialize ‘Lorelin,’ a prostate cancer treatment, using our proprietary DDS platform technologies such as microspheres, and continue developing new products, including treatments for obesity and acromegaly.”

Economy

Corporation

IT·Science

Economy

LGELECTRONICS Enhances Safety and Quality of Humanoid Robots…Aiming to Secure Reliability Early On

LGELECTRONICS is partnering with the Korea Robot Industry Promotion Agency to enhance the safety and quality competitiveness of humanoid robots. Ahead of the unveiling of a bipedal robot in the first …
2026-11-16 10:09:25

Corporation

S-CHEM Targets Semiconductor Materials Market with OLED Technology… Plans to Begin SOH Supply by Year-End

#S-CHEM is entering the semiconductor materials market by leveraging the synthesis and purification technologies it has developed in the field of organic light-emitting diode (OLED) materials. Having …
2026-11-16 09:49:41

IT·Science

DongKook Pharmaceutical Co.,Ltd. Reports Cumulative Third-Quarter Sales of 768.6 Billion… Driven by Overseas Beauty Sales

DongKook Pharmaceutical Co.,Ltd.(086450)reported year-over-year increases in both cumulative revenue and operating profit for the first three quarters of this year. Growth was driven by expanded overs…
2026-11-16 10:24:02